Health Sciences Authority

<h1>Health Sciences Authority</h1> <p>The <strong>Health Sciences Authority (HSA)</strong> is Singapore's multidisciplinary health-sciences and regulatory agency. HSA was established as a statutory board under the Ministry of Health on <strong>1 April 2001</strong>, integrating five former national agencies (<a href="https://www.hsa.gov.sg/about-us/milestones-and-achievements/milestones/">HSA, milestones</a>). Its mission is to regulate health products wisely, serve the administration of justice, secure the nation's blood supply and safeguard public health (<a href="https://www.hsa.gov.sg/about-us/about-hsa/vision-mission-values/">HSA, vision, mission and values</a>).</p> <h2>Three professional groups and core functions</h2> <p>HSA describes three core areas of work. <strong>Health Products Regulation</strong> regulates health products against standards of safety, quality and efficacy, covering work such as product registration, licensing and post-market safeguards for relevant product classes. <strong>Blood Services</strong> secures a safe and adequate blood supply for public and private hospitals, alongside blood-banking and specialised laboratory work supporting transfusion and transplantation medicine. <strong>Applied Sciences</strong> provides forensic medicine, forensic science and analytical-chemistry testing that supports the administration of justice and public health (<a href="https://www.hsa.gov.sg/about-us/">HSA, About us</a>, accessed 28 October 2026). These functions make HSA both a health-products regulator and a national scientific service. A question about a product licence, a blood donation or a forensic laboratory service may therefore involve different HSA teams and rules; “HSA” is not synonymous with a single licensing process.</p> <h2>Health-products regulation</h2> <p>HSA's regulatory scope includes product registration, licensing, notifications, advertisements and safety monitoring across different product classes. The exact route depends on the product: HSA separately describes pathways for therapeutic products, medical devices, cell, tissue and gene therapy products, cosmetics, Chinese proprietary medicines, traditional medicines, health supplements, tobacco products and other regulated products (<a href="https://www.hsa.gov.sg/">HSA, home</a>, accessed 28 October 2026). A product appearing on an HSA pathway does not mean that every product class has identical pre-market requirements, licence conditions or evidence standards.</p> <p>HSA's regulatory role also supports Singapore's biomedical and pharmaceutical ecosystem. Its decisions and scientific assessments concern regulated products and public-health safeguards; they should not be interpreted as a guarantee that a product is clinically appropriate for every individual or as a substitute for advice from a healthcare professional.</p> <h2>How therapeutic medicines and vaccines are registered</h2> <p>Before a therapeutic product can be supplied in Singapore, HSA requires product registration and evaluates scientific evidence on quality, safety and efficacy. A local ACRA-registered company applies; the route depends on the product and application category. HSA distinguishes new-drug applications (including new chemical or biological entities and certain new formulations or uses) from generic-drug applications. Its evaluation routes include full, abridged and verification pathways, with eligibility depending in part on the product and prior decisions by overseas regulators. A foreign approval can support an eligible route, but it does not automatically register the product in Singapore or oblige HSA to approve it. HSA assesses whether the benefit-risk balance is acceptable for the proposed use (<a href="https://www.hsa.gov.sg/therapeutic-products/registration-of-therapeutic-products/register-your-therapeutic-product/registration-of-therapeutic-products/overview/">HSA, registration overview, updated 4 May 2026</a>; <a href="https://www.hsa.gov.sg/therapeutic-products/registration-of-therapeutic-products/register-your-therapeutic-product/registration-of-therapeutic-products/application-types/">application types, updated 17 July 2026</a>; <a href="https://www.hsa.gov.sg/therapeutic-products/registration-of-therapeutic-products/register-your-therapeutic-product/registration-of-therapeutic-products/evaluation-routes/">evaluation routes, updated 13 March 2026</a>).</p> <p>HSA classifies vaccines made from whole microorganisms or their components as biological therapeutic products. Some vaccines may require HSA to contextualise the benefit-risk assessment for local disease epidemiology, medical practice or public-health conditions; HSA specifically notes vaccines as an example where a verification route may not be suitable. Registration is also distinct from a further operational requirement: HSA's registration resources state that importers must notify lot-release information for imported registered vaccines before local supply. To check a product's Singapore registration, use HSA's Register of Therapeutic Products and the entry for the exact product, not a foreign regulator's listing alone (<a href="https://www.hsa.gov.sg/therapeutic-products/registration-of-therapeutic-products/register-your-therapeutic-product/registration-of-therapeutic-products/overview/">HSA registration overview</a>; <a href="https://www.hsa.gov.sg/therapeutic-products/registration-of-therapeutic-products/register-your-therapeutic-product/registration-of-therapeutic-products/evaluation-routes/">evaluation routes</a>; <a href="https://www.hsa.gov.sg/therapeutic-products/registration-of-therapeutic-products/register-your-therapeutic-product/">registration resources</a>).</p> <p>Product registration is not the same question as whether a vaccine is recommended, subsidised or offered to a particular population. Those public-health recommendations and delivery arrangements are described in Singapore's national immunisation guidance, including the NCIS and NAIS published by the Communicable Diseases Agency; they do not replace HSA's product-level regulatory decision (<a href="https://www.cda.gov.sg/public/vaccinations/">CDA, Vaccinations</a>; see <a href="/en/knowledge/article/sgkb.healthcare.public-health-and-disease-control">public health and disease control</a>). A medicine's HSA registration likewise does not determine that it is suitable for every patient, available at every clinic or funded under a national programme.</p> <h2>Blood and applied-science services</h2> <p>Through Blood Services, HSA operates the national blood-service function and works to maintain a safe and adequate supply for hospitals (<a href="https://www.hsa.gov.sg/about-us/">HSA, About us</a>). Through Applied Sciences, it contributes specialised forensic, investigative and analytical capabilities to the administration of justice. The two functions have different users and decision contexts: blood services support transfusion and hospital supply, while applied-science services support justice, public-health and government investigations. Neither should be collapsed into the health-products licensing function.</p> <p>For retrieval purposes, these services also imply different next steps. A person seeking to donate blood or understand blood-bank services should use HSA's blood-services and donation information; a court, investigator or public agency seeking laboratory or forensic support should use the relevant applied-science channel. Neither service is a general clinical-care provider, and the About Us description does not turn an analytical result into a diagnosis or a forensic examination into a regulatory approval. Keeping these boundaries explicit helps distinguish HSA from hospitals, MOH policy functions and product manufacturers while retaining the agency's shared public-health mission.</p> <h2>HSA's current strategic framework</h2> <p>In its <strong>2025/26 annual-report introduction</strong>, HSA says its 5P strategic framework—<strong>Products, Platforms, People, Partnerships and Profiling</strong>—has guided its work since 2025. The agency describes the pillars as complementary: strengthening the products and services it regulates or provides, modernising operating platforms, developing its workforce, extending impact through partnerships, and positioning HSA as a trusted scientific agency locally and internationally. HSA frames this agenda against changes including artificial intelligence, advanced therapeutics, digital healthcare and cross-border risks (<a href="https://www.hsa.gov.sg/about-us/">HSA, About us and Annual Report 2025/26</a>, page last updated 21 September 2026 and accessed 28 October 2026).</p> <p>The 5P framework is HSA's organisational strategy, not a separate licence, regulator or statutory list of functions. It helps explain how HSA presents its evolving role, but it does not by itself transfer a function from MOH or professional boards; the dated two-phase transition below is the controlling source for those responsibility changes (<a href="https://www.hsa.gov.sg/about-us/">HSA, About us and Annual Report 2025/26</a>; <a href="https://www.hsa.gov.sg/healthreg/">HSA, integrated healthcare regulation</a>, accessed 28 October 2026).</p> <h2>Integrated healthcare-regulation transition</h2> <p>The <strong>Health Sciences Authority (Amendment) and Other Matters Act 2026</strong> (No. 22 of 2026) was passed by Parliament on <strong>9 September 2026</strong> and assented to by the President on <strong>24 September 2026</strong> (<a href="https://sso.agc.gov.sg/Acts-Supp/22-2026/Published/20261005?DocDate=20261005">Singapore Statutes Online, Act 22 of 2026</a>). HSA's integrated-regulation page, updated <strong>6 November 2026</strong>, identifies <strong>Phase 1 as effective from 1 November 2026</strong>: MOH's Health Regulation Group (HRG) manpower and functions moved to HSA, including administration, licensing operations, inspections, audits and enforcement for specified regimes. The operational transfer is Act-specific; it does not mean HSA becomes the named statutory authority for every decision. For example, MOH remains the licensing authority under the Healthcare Services Act (HCSA), and HCSA licences continue to be granted in MOH's name, while HSA administers and processes applications through the Healthcare Application and Licensing Portal (HALP) at <code>halp.hsa.gov.sg</code>. Existing HCSA licensees do not need to reapply. Applications submitted and still being processed as at <strong>31 October 2026</strong> are handed over to HSA and continue without resubmission, unless HSA advises otherwise or asks for more information (<a href="https://www.hsa.gov.sg/healthreg/">HSA, integrated healthcare regulation, updated 6 November 2026</a>).</p> <p>For the Human Biomedical Research Act (HBRA), HSA administers the regime and grants future approvals, while existing approvals remain valid without reapplication. HSA administers the Biological Agents and Toxins Act (BATA), including facility and certification-body matters; existing approvals remain valid and requirements are unchanged. Under the Health Information Act (HIA), MOH remains the authority while HSA manages compliance and enforcement; NEHR access continues as normal. HSA also takes over the Health Sector Administrator role for health charities, with current approvals preserved. HSA's existing Health Products Act (HPA) product-registration and dealer-licensing functions continue unchanged; they were not newly transferred MOH functions. Across these regimes, operational administration, enforcement powers and the authority that grants a licence or remains accountable for the Act are not always vested in the same agency. Existing submission channels, processing arrangements and requirements continue through the transition (<a href="https://www.hsa.gov.sg/healthreg/">HSA, integrated healthcare regulation, updated 6 November 2026</a>).</p> <p><strong>Phase 2 is planned by end-2027</strong> and concerns Secretariat of healthcare Professional Boards (SPB) manpower and functions for reviewing and developing policies, guidelines and processes that support the Professional Boards and Councils. The page distinguishes this secretariat support from professional regulation itself: registration and other regulatory matters for healthcare professionals remain with SPB until further communication. The professional boards remain the bodies whose statutory mandates govern their respective professions; the organisational move does not mean HSA makes all professional registration decisions. A doctor's or nurse's professional registration was not part of the Phase 1 transfer (<a href="https://www.hsa.gov.sg/healthreg/">HSA, integrated healthcare regulation, updated 6 November 2026</a>).</p> <p>HSA says stakeholders and licensees generally need not reapply for existing licences, approvals or registrations, and that submission channels, processing arrangements and regulatory requirements continue through the transition. As of 6 November 2026, Phase 1 is in effect and Phase 2 remains planned by end-2027. HSA's guidance continues to distinguish operational processing and enforcement from the authority in whose name a licence or approval is issued (<a href="https://www.hsa.gov.sg/healthreg/">HSA, integrated healthcare regulation, updated 6 November 2026</a>).</p> <p>The transition brings regulation of healthcare services, products, information, biomedical research, healthcare charities and professional-regulation support into a more integrated hub (<a href="https://www.hsa.gov.sg/healthreg/">HSA, integrated healthcare regulation, updated 6 November 2026</a>). HSA's About page, last updated 21 September and rechecked 28 October 2026, describes three distinct core functions—health-products regulation, blood services, and applied sciences supporting justice—which remain useful when distinguishing longstanding roles from the new cross-government transition (<a href="https://www.hsa.gov.sg/about-us/">HSA, About us</a>). HSA's milestones page, last updated 13 March 2026 and accessed 28 October, records that in 2025 it implemented a Next-Gen Blood Supply Management System across all public hospitals, illustrating that the authority's operational role includes national systems as well as licensing and enforcement. Existing HSA product-regulation pages and the separate professional-board framework should therefore be read with the applicable phase and effective date in mind.</p> <h2>Critical perspective: integrated operations and statutory accountability</h2> <p>An integrated operational hub can make coordination across related regulatory work more coherent, which is the stated direction of HSA's plan. The same announcement, updated <strong>6 November 2026</strong>, preserves separate lines of statutory accountability: MOH continues to grant HCSA licences in its own name and remains the HIA authority, while HSA administers or enforces specified functions; professional registration remains with the Professional Boards during Phase 1. The practical trade-off is that a more consolidated service interface does not automatically simplify every question about who has legal authority to decide, issue a licence or register a practitioner. This is an interpretation of the published allocation of functions, not evidence of service disruption or a claim that accountability has weakened. Users should identify the relevant Act and transaction, then distinguish application processing, inspection or enforcement from the statutory body named as decision-maker (<a href="https://www.hsa.gov.sg/healthreg/">HSA, integrated healthcare regulation, updated 6 November 2026</a>).</p>

简介

卫生科学局

**卫生科学局(HSA)**是新加坡的多学科健康科学与监管机构。HSA 于 2001 年四月 1 日成立,是卫生部属下的法定机构,由五个原有国家机构合并而成(HSA,里程碑)。其使命是审慎监管健康产品、服务司法行政、保障国家血液供应并维护公共卫生(HSA,愿景、使命与价值观)。

三个专业领域与核心职能

HSA 将其核心工作概括为三个领域。健康产品监管按照安全、质量和功效标准监管健康产品,工作包括相关产品类别的产品注册、执照发放和上市后保障。血液服务为公立和私立医院保障安全且充足的血液供应,并提供支持输血和移植医学的血库及专门实验室工作。应用科学提供法医学、法证科学和分析化学检测,以支持司法行政和公共卫生(HSA,关于我们,查阅于 2026 年十月 28 日)。这些职能使 HSA 既是健康产品监管机构,也是国家科学服务机构。因此,关于产品执照、献血或法证实验室服务的问题,可能涉及 HSA 内不同团队及不同规则;“HSA”并不等同于单一的执照申请流程。

健康产品监管

HSA 的监管范围涵盖不同产品类别的产品注册、执照、通知、广告和安全监测。具体途径取决于产品:HSA 分别说明治疗产品、医疗器械、细胞、组织和基因治疗产品、化妆品、中成药、传统药物、保健品、烟草产品及其他受监管产品的申请途径(HSA,主页,查阅于 2026 年十月 28 日)。某产品列入 HSA 的申请途径,并不意味着每个产品类别都适用相同的上市前要求、执照条件或证据标准。

HSA 的监管职能也支持新加坡的生物医学和制药生态系统。其决定和科学评估涉及受监管产品及公共卫生保障;不应将其解读为保证某产品适合每个人临床使用,也不能代替医疗专业人员的建议。

治疗药物和疫苗如何注册

治疗产品在新加坡供应前,HSA 要求其完成产品注册,并评估有关质量、安全性和功效的科学证据。申请人须为在新加坡会计与企业管理局(ACRA)注册的本地公司;申请途径取决于产品和申请类别。HSA 将新药申请(包括新的化学或生物实体,以及某些新剂型或新用途)与仿制药申请区分开来。其评估途径包括全面、简化和验证途径,是否符合资格部分取决于产品以及海外监管机构此前作出的决定。外国批准可支持符合资格的申请途径,但不会自动使产品在新加坡注册,也不要求 HSA 必须批准该产品。HSA 会评估拟议用途的获益风险平衡是否可接受(HSA,注册概览,更新于 2026 年五月 4 日;申请类型,更新于 2026 年七月 17 日;评估途径,更新于 2026 年三月 13 日)。

HSA 将由完整微生物或其组成部分制成的疫苗归类为生物治疗产品。对于某些疫苗,HSA 可能需要结合本地疾病流行病学、医疗实践或公共卫生状况来进行获益风险评估;HSA 特别指出,疫苗就是验证途径可能不适用的例子。注册与另一项后续运营要求也有所不同:HSA 的注册资料指出,进口商必须在已注册的进口疫苗于本地供应前,通知批次放行信息。如需确认产品是否已在新加坡注册,应查阅 HSA 的治疗产品注册名册中该确切产品的条目,不能只依据外国监管机构的名录(HSA 注册概览;评估途径;注册资料)。

产品注册并不等同于疫苗是否获推荐、获补贴或向特定人群提供。这些公共卫生建议和接种安排载于新加坡国家免疫接种指南,包括传染病管理局发布的 NCIS 和 NAIS;它们不能取代 HSA 对产品作出的监管决定(CDA,疫苗接种;另见公共卫生与疾病控制)。药物获 HSA 注册,也不代表它适合每位患者、在每家诊所都有供应,或由国家计划资助。

血液与应用科学服务

HSA 通过血液服务负责国家血液服务职能,并致力于维持医院安全且充足的血液供应(HSA,关于我们)。HSA 通过应用科学为司法行政提供专门的法证、调查和分析能力。这两项职能的服务对象和决策场景不同:血液服务支持输血和医院供血;应用科学服务则支持司法、公共卫生和政府调查。两者都不应与健康产品执照职能混为一谈。

在查找资料时,这些服务也意味着不同的后续步骤。想献血或了解血库服务的人,应查阅 HSA 的血液服务和献血信息;寻求实验室或法证支持的法院、调查人员或公共机构,应联系相关应用科学渠道。这两类服务都不是一般临床护理服务提供者;“关于我们”页面的介绍也不会将分析结果变成诊断,或将法证检查变成监管批准。明确这些界限,有助于在保留该机构共同公共卫生使命的同时,将 HSA 与医院、卫生部政策职能及产品制造商区分开来。

HSA 当前的战略框架

在其 2025/26 年年报导言中,HSA 表示,自 2025 年以来,其 5P 战略框架——产品(Products)、平台(Platforms)、人才(People)、伙伴关系(Partnerships)和定位(Profiling)——一直指导该局的工作。该局将这些支柱描述为相辅相成:加强其监管或提供的产品和服务、更新运营平台、培养员工队伍、通过伙伴关系扩大影响力,并将 HSA 定位为本地及国际上值得信赖的科学机构。HSA 将这项议程置于人工智能、先进疗法、数码医疗和跨境风险等变化的背景下(HSA,关于我们及 2025/26 年年报,网页最后更新于 2026 年九月 21 日,查阅于 2026 年十月 28 日)。

5P 框架是 HSA 的组织战略,并非一项独立执照、监管机构或法定职能清单。它有助于说明 HSA 如何阐述其不断变化的角色,但本身并不会将职能从卫生部或专业委员会移交出去;下文注明日期的两阶段转移安排才是这些职责变动的依据(HSA,关于我们及 2025/26 年年报;HSA,综合医疗监管,查阅于 2026 年十月 28 日)。

综合医疗监管职能转移

《2026 年卫生科学局(修正案)及其他事项法令》(2026 年第 22 号法令)于 2026 年九月 9 日经国会通过,并于 2026 年九月 24 日获总统批准(新加坡法规在线,2026 年第 22 号法令)。HSA 的综合监管页面于 2026 年十一月 6 日更新,指出第 1 阶段自 2026 年十一月 1 日起生效:卫生部健康监管组(HRG)的人员和职能已转至 HSA,包括指定监管制度下的行政、执照运营、检查、审计和执法工作。这项运营职能转移仅适用于该法令指定的事项;这并不意味着 HSA 成为每项决定所指明的法定主管机构。例如,卫生部仍是《医疗服务法》(HCSA)下的执照主管机构,HCSA 执照继续以卫生部名义发出;HSA 则通过医疗申请与执照门户(HALP,网址为 halp.hsa.gov.sg)管理和处理申请。现有 HCSA 持牌人无需重新申请。截至 2026 年十月 31 日已提交且仍在处理中的申请会移交 HSA,并继续处理,无需重新提交,除非 HSA 另有通知或要求提供更多资料(HSA,综合医疗监管,更新于 2026 年十一月 6 日)。

对于《人体生物医学研究法》(HBRA),HSA 负责管理该制度并批准今后的申请,现有批准继续有效,无需重新申请。HSA 负责管理《生物制剂与毒素法》(BATA),包括设施和认证机构事项;现有批准继续有效,要求维持不变。根据《健康信息法》(HIA),卫生部仍是主管机构,HSA 负责管理合规和执法;全国电子健康记录(NEHR)的访问照常进行。HSA 也接管了卫生慈善机构的卫生领域主管机构职能,现有批准继续有效。HSA 原有的《健康产品法》(HPA)产品注册和经销商执照职能继续不变;这些并非新移交给 HSA 的卫生部职能。在这些监管制度中,运营管理、执法权力,以及发出执照或对该法令负有问责责任的主管机构,并不总是由同一个机构承担。现有提交渠道、处理安排和要求在过渡期间继续适用(HSA,综合医疗监管,更新于 2026 年十一月 6 日)。

第 2 阶段计划于 2027 年底前实施,涉及医疗专业委员会秘书处(SPB)人员和职能,负责审查和制定政策、指南和流程,以支持专业委员会和理事会。页面将这类秘书处支持与专业监管本身区分开来:在另行通知之前,医疗专业人员的注册及其他监管事项仍由 SPB 负责。各专业委员会仍是其相应专业法定职责的执行机构;组织职能转移并不意味着 HSA 会作出所有专业注册决定。医生或护士的专业注册不属于第 1 阶段转移范围(HSA,综合医疗监管,更新于 2026 年十一月 6 日)。

HSA 表示,利益相关者和持牌人通常无需为现有执照、批准或注册重新申请,提交渠道、处理安排和监管要求在过渡期间也会继续适用。截至 2026 年十一月 6 日,第 1 阶段已经生效,第 2 阶段仍计划于 2027 年底前实施。HSA 的指引继续区分运营处理和执法职能,以及以其名义发出执照或批准的主管机构(HSA,综合医疗监管,更新于 2026 年十一月 6 日)。

这项转移将医疗服务、产品、信息、生物医学研究、医疗慈善机构和专业监管支持的监管工作纳入更综合的中心(HSA,综合医疗监管,更新于 2026 年十一月 6 日)。HSA 的“关于我们”页面最后于九月 21 日更新,并于 2026 年十月 28 日重新查阅;页面描述了三个不同的核心职能——健康产品监管、血液服务,以及支持司法的应用科学。这些职能仍有助于区分长期职责与新的跨政府职能转移(HSA,关于我们)。HSA 的里程碑页面最后于 2026 年三月 13 日更新,并于十月 28 日查阅;页面记录该局于 2025 年在所有公立医院实施新一代血液供应管理系统,说明该机构的运营角色除执照和执法之外,也包括国家系统。阅读 HSA 现有产品监管页面及独立的专业委员会制度时,应结合适用的阶段和生效日期。

重要视角:综合运营与法定问责

综合运营中心可以让相关监管工作的协调更加连贯,这正是 HSA 计划提出的方向。该公告于 2026 年十一月 6 日更新,同时保留了不同的法定问责关系:卫生部继续以自身名义发出 HCSA 执照,并继续作为 HIA 主管机构;HSA 则负责管理或执法指定职能;在第 1 阶段期间,专业注册仍由专业委员会负责。实际上的取舍在于,服务界面的整合程度提高,并不会自动简化所有有关谁有权依法作出决定、发出执照或注册从业者的问题。这是对已公布职能分配的解读,并非服务中断的证据,也不代表问责有所削弱。用户应先确认相关法令和事项,再区分申请处理、检查或执法职能与法定决策机构(HSA,综合医疗监管,更新于 2026 年十一月 6 日)。